DE602004008474D1 - N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden. - Google Patents

N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden.

Info

Publication number
DE602004008474D1
DE602004008474D1 DE602004008474T DE602004008474T DE602004008474D1 DE 602004008474 D1 DE602004008474 D1 DE 602004008474D1 DE 602004008474 T DE602004008474 T DE 602004008474T DE 602004008474 T DE602004008474 T DE 602004008474T DE 602004008474 D1 DE602004008474 D1 DE 602004008474D1
Authority
DE
Germany
Prior art keywords
sulfonylheterocyclopyrrolyl
hydroxytryptamine
ligands
alkylamine compounds
alkylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004008474T
Other languages
English (en)
Other versions
DE602004008474T2 (de
Inventor
Derek Cecil Cole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of DE602004008474D1 publication Critical patent/DE602004008474D1/de
Application granted granted Critical
Publication of DE602004008474T2 publication Critical patent/DE602004008474T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE602004008474T 2003-07-31 2004-07-23 N-sulfonylheterocyclopyrrolylalkylamin-verbindungen als 5-hydroxytryptamin-6-liganden. Expired - Fee Related DE602004008474T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49162203P 2003-07-31 2003-07-31
US491622P 2003-07-31
PCT/US2004/023993 WO2005012311A1 (en) 2003-07-31 2004-07-23 N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands

Publications (2)

Publication Number Publication Date
DE602004008474D1 true DE602004008474D1 (de) 2007-10-04
DE602004008474T2 DE602004008474T2 (de) 2008-05-15

Family

ID=34115532

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004008474T Expired - Fee Related DE602004008474T2 (de) 2003-07-31 2004-07-23 N-sulfonylheterocyclopyrrolylalkylamin-verbindungen als 5-hydroxytryptamin-6-liganden.

Country Status (14)

Country Link
US (2) US7041695B2 (de)
EP (1) EP1648904B1 (de)
JP (1) JP2007500701A (de)
CN (1) CN100443487C (de)
AT (1) ATE370955T1 (de)
AU (1) AU2004261606A1 (de)
BR (1) BRPI0413158A (de)
CA (1) CA2532382A1 (de)
DE (1) DE602004008474T2 (de)
DK (1) DK1648904T3 (de)
ES (1) ES2290740T3 (de)
MX (1) MXPA06000957A (de)
PL (1) PL1648904T3 (de)
WO (1) WO2005012311A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648904B1 (de) * 2003-07-31 2007-08-22 Wyeth N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden.
GB0403781D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical compounds
US7314875B2 (en) 2004-04-13 2008-01-01 Cephalon, Inc. Tricyclic aromatic and bis-phenyl sulfinyl derivatives
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
BRPI0611948A2 (pt) * 2005-06-17 2010-10-13 Wyeth Corp compostos úteis como inibidores de serotonina e agonistas de antagonista de 5-ht1a
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
US20080262228A1 (en) * 2006-11-28 2008-10-23 Wyeth Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2053052A1 (de) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Verfahren zur Herstellung von 6-substituiertem Imidazo[2,1-b]thiazol-5-sulfonylhalogenid
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2019012728A (es) 2017-04-24 2020-01-23 Bayer Ag Derivados de heterociclos biciclicos fusionados como plaguicidas.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2537974A1 (fr) * 1982-12-16 1984-06-22 Adir Nouveaux derives de thieno (2,3-b) pyrrole, leur procede de preparation et les compositions pharmaceutiques les renfermant
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
AU767009B2 (en) * 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
GB0016454D0 (en) * 2000-07-04 2000-08-23 Hoffmann La Roche Thienopyrrolidinones
DE10063992A1 (de) 2000-12-21 2002-07-04 Max Planck Gesellschaft Tryptophan-Analoga in Proteinen, Peptiden und peptidischen Leitstrukturen
DK1355900T3 (da) * 2000-12-22 2006-09-11 Wyeth Corp Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
US6730694B1 (en) * 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
CN1309385C (zh) * 2001-12-20 2007-04-11 惠氏公司 作为5－羟色胺－6配体的吲哚基烷基胺衍生物
TW200407127A (en) 2002-08-21 2004-05-16 Astrazeneca Ab Chemical compounds
US7317010B2 (en) * 2002-08-21 2008-01-08 Astrazeneca Ab Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
EP1648904B1 (de) * 2003-07-31 2007-08-22 Wyeth N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden.

Also Published As

Publication number Publication date
WO2005012311A1 (en) 2005-02-10
US7041695B2 (en) 2006-05-09
PL1648904T3 (pl) 2008-01-31
DE602004008474T2 (de) 2008-05-15
DK1648904T3 (da) 2007-10-22
ATE370955T1 (de) 2007-09-15
CN100443487C (zh) 2008-12-17
CA2532382A1 (en) 2005-02-10
EP1648904B1 (de) 2007-08-22
JP2007500701A (ja) 2007-01-18
US20050038088A1 (en) 2005-02-17
BRPI0413158A (pt) 2006-10-03
MXPA06000957A (es) 2006-03-30
CN1826346A (zh) 2006-08-30
AU2004261606A1 (en) 2005-02-10
US20060160878A1 (en) 2006-07-20
EP1648904A1 (de) 2006-04-26
US7220756B2 (en) 2007-05-22
ES2290740T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
SE0302232D0 (sv) Novel Compounds
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
NO20050014L (no) 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander
NO20050007L (no) 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander
NO20070606L (no) Inhibitorer av IAP
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
ATE466860T1 (de) Cgrp-rezeptorantagonisten
EA200700909A1 (ru) Азаиндолкарбоксамиды
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
DE602004008474D1 (de) N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden.
MXPA04003087A (es) Derivados de cromano como ligados de 5-hidroxitriptamina-6.
ATE368040T1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren
EA200700707A1 (ru) Производные 2-ациламинотиазола
MX2008002158A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
UA94053C2 (ru) Замещенные производные 3-сульфонилиндазола в качестве лигандов гидрокситриптамина-6
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
BRPI0416371A (pt) composto de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligantes de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee